Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The New Quad: FDA Approves Gilead’s 4-In-1 HIV Pill Stribild

This article was originally published in The Pink Sheet Daily

Executive Summary

With cost concerns already arising, the sponsor says it is working to ensure the drug is covered by state AIDS Drug Assistance Programs.

You may also be interested in...



With Parity Pricing, Gilead Relies On Genvoya Safety To Convert From Stribild

Genvoya includes a much smaller dose of tenofovir than Stribild, allowing for smaller pills, while its label also includes a number of safety advantages that Gilead can use in marketing.

Gilead: Three HIV Launches Expected In Near-Term Future

Sales are strong, especially for Stribild, but Gilead is planning ahead for the patent expiration of Viread and replacing it in combo regimens with a new formulation of tenofovir that offers enhanced therapeutic benefits.

Deal Watch: Hep C M&A Still Thriving; Plus AstraZeneca/Synairgen, MorphoSys/Merck Serono, ViiV/J&J

Merck beats out bids from AbbVie and Johnson & Johnson for Idenix Pharmaceuticals, gaining possession of three promising HCV drug candidates.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel